BDRX - Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why | Benzinga
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) announced progress on eRapa, its drug to treat Familial Adenomatous Polyposis (FAP), an inherited disorder characterized by cancer of the large intestine (colon) and rectum.
12-month data from a phase 2 clinical trial were recently presented at the 2024 InSIGHT biannual meeting.
With FAP, hundreds or thousands of precancerous polyps grow throughout the gastrointestinal tract. There is no approved therapeutic option for treating FAP patients.
Biodexa believes eRapa ...